This functionality is implemented using Javascript. It cannot work without it, etc...

Estamos cargando la información...

Saltar al contenido

Monoclonal Antibody Therapies for Migraine Prevention

Subcutaneously administered Food and Drug Administration (FDA)-approved monoclonal antibodies for calcitonin gene-related peptide may be considered medically necessary for the preventive treatment of episodic or chronic migraine under the following conditions:
The patient is ≥ 18 years of age; AND

Has ≥ 4 migraine headache days per month; AND

Has failed a trial (eg, not effective or not tolerated) from ≥ 3 classes of prophylactic pharmacologic therapies (eg, anti-depressants, anticonvulsants, and beta-blockers, if not contraindicated) AND;

Has not received botulinum toxin headache prophylaxis in the past 4 months.

Intravenously administered FDA-approved monoclonal antibody for calcitonin gene-related peptide may be considered medically necessary for the preventive treatment of episodic or chronic migraine under the following conditions:

The patient is ≥ 18 years of age; AND

Has ≥ 4 migraine headache days per month; AND

Has failed a trial (eg, not effective or not tolerated) from ≥ 3 classes of prophylactic pharmacologic therapies (eg, anti-depressants, anticonvulsants, and beta-blockers, if not contraindicated) AND;

Has not received botulinum toxin headache prophylaxis in the past 4 months.

Galcanezumab may be considered medically necessary for the treatment of episodic cluster headaches under the following conditions:

The patient is ≥ 18 years of age; AND

Patient has been diagnosed with episodic cluster headaches as defined as having at least 2 cluster periods lasting from 7 days to 1 year, separated by pain-free remission periods lasting at least 1 month;

Patient has been unable to achieve a reduction in weekly cluster headache attack frequency with preventative medication(s).

Treatment with monoclonal antibodies for calcitonin gene-related peptide is considered investigational in all other situations including treatment of acute migraine.

787-277-6653 787-474-6326